title: Interferon impedes an early step of hepatitis delta virus infection.
abstract: Hepatitis delta virus (HDV) infects hepatocytes, the major cell type of the liver. Infection of the liver may be either transient or chronic. The prognosis for patients with chronic HDV infection is poor, with a high risk of cirrhosis and hepatocellular carcinoma. The best antiviral therapy is weekly administration for at least one year of high doses of interferon alpha. This efficacy of interferon therapy has been puzzling in that HDV replication in transfected cell lines is reported as insensitive to administration of interferon alpha or gamma. Similarly, this study shows that even when an interferon response was induced by transfection of poly(IC) into a cell line, HDV RNA accumulation was only modestly inhibited. However, when the HDV replication was initiated by infection of primary human hepatocytes, simultaneous addition of interferons alpha or gamma at 600 units/ml, a concentration comparable to that achieved in treated patients, the subsequent HDV RNA accumulation was inhibited by at least 80%. These interferon treatments were shown to produce significant time-dependent increases of host response proteins such as for Stat-1, phosphoStat-1, Mx1/2/3 and PKR, and yet interferon pretreatment of hepatocytes did not confer an increased inhibition of HDV replication over interferon treatment at the time of (or after) infection. These and other data support the interpretation that interferon action against HDV replication can occur and is largely mediated at the level of entry into primary human hepatocytes. Thus in vivo, the success of long-term interferon therapy for chronic HDV, may likewise involve blocking HDV spread by interfering with the initiation of productive infection of naïve hepatocytes.
authors.affiliation: Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America.
authors.forename: Ziying
authors.initials: Z
authors.lastname: Han
authors.forename: Shoko
authors.initials: S
authors.lastname: Nogusa
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Nicolas
authors.forename: Siddharth
authors.initials: S
authors.lastname: Balachandran
authors.forename: John
authors.initials: J
authors.lastname: Taylor
mesh_terms: D002478:Cells, Cultured; D057809:HEK293 Cells; D003699:Hepatitis D / Q000821:virology*; D003698:Hepatitis Delta Virus / Q000187:drug effects* / Q000502:physiology*; D022781:Hepatocytes / Q000187:drug effects / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology; D011070:Poly I-C / Q000378:metabolism; D013997:Time Factors; D014162:Transfection; D018116:Vesiculovirus / Q000187:drug effects / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D016898:Interferon-alpha; D010455:Peptides; D007371:Interferon-gamma; D011070:Poly I-C